Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 229

Sort by

Sort Order Select

Journal Articles

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 137 (13): 1754–1764.

https://doi.org/10.1182/blood.2020006334

Published: 2021

Includes: Supplemental data

Journal Articles

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Pablo Domizi, PhD, Astraea Jager, BS, Jolanda Sarno, PhD, Charles G. Mullighan, MBBS, MD, Stephan Grupp, MD PhD, Elena Sotillo, PhD, David M. Barrett, Kara L. Davis, DO

Blood (2019) 134 (Supplement_1): 749.

https://doi.org/10.1182/blood-2019-128883

Published: 2019

Journal Articles

Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial

Blood (2019) 134 (Supplement_1): 826.

https://doi.org/10.1182/blood-2019-123613

Published: 2019

Journal Articles

Understanding How Fc-Modification Transforms a Pathogenic Heparin-Induced Thrombocytopenia (HIT)-like Monoclonal Antibody into a Novel Treatment for Sepsis

Kandace Gollomp, MD, Amrita Sarkar, PhD, Gowthami Arepally, MD, Douglas B. Cines, MD, M. Anna Kowalska, PhD, Lubica Rauova, MD PhD, Mortimer Poncz, MD

Blood (2019) 134 (Supplement_1): 10.

https://doi.org/10.1182/blood-2019-123132

Published: 2019

Journal Articles

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Andrea Iannello, PhD, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Elisa Marchi, Richard R. Furman, MD, John N. Allan, MD, Silvia Coma, PhD, Jonathan A. Pachter, PhD, Silvia Deaglio, MD PhD, Tiziana Vaisitti, PhD

Blood (2019) 134 (Supplement_1): 2862.

https://doi.org/10.1182/blood-2019-125754

Published: 2019

Journal Articles

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Pauline De Malglaive, MD, Matthieu Groh, MD, Guillaume Lefèvre, MD PhD, Chafika Morati Hafsaoui, MD, Magda Alexis, MD, Mathilde Hunault, MD PhD, Julien Seneschal, MD PhD, Hilaire Charlanne, MD, Claude Preudhomme, PharmD, PhD, Bernard Bonnotte, MD PhD, Jean Emmanuel Kahn, PhDMD

Blood (2019) 134 (Supplement_1): 2322.

https://doi.org/10.1182/blood-2019-131687

Published: 2019

Journal Articles

Telomere Elongation and Clinical Improvement in Telomeropathy Patients: A Prospective Clinical Trial of Nandrolone in Telomeropathies

Diego V Clé, MD PhD, Luiz Fernando Catto, MD, Luiz Guilherme Darrigo, PhD, Elvis Valera, Fernanda Gutierrez-Rodrigues, PhD, Flavia S. Donaires, PhD, André Pinto, Renan C. Albino, Bárbara Santana, Jose Baddini-Martinez, MD PhD, Rodrigo T. Calado, MD PhD

Blood (2019) 134 (Supplement_1): 2501.

https://doi.org/10.1182/blood-2019-130844

Published: 2019

Journal Articles

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Anthony R. Mato, MDMSCE, Ian W. Flinn, MD PhD, John M. Pagel, MD PhD DSc, Jennifer R. Brown, MD PhD, Chan Y. Cheah, Catherine C. Coombs, MD, Manish R. Patel, MD, S. Michael Rothenberg, MD PhD, Donald E. Tsai, MD PhD, Nora C. Ku, MD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 501.

https://doi.org/10.1182/blood-2019-127509

Published: 2019

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Susan Prockop, MD, Ran Reshef, MDMSc, Donald E. Tsai, MD PhD, Nancy Bunin, MD, Rolla Abu-Arja, MD, Kris Michael Mahadeo, MD, Wen-Kai Weng, MD PhD, Koen Van Besien, MD PhD, David Loeb, MD PhD, Sunita Dwivedy Nasta, MD, Eneida R. Nemecek, MDMBA,MSc, Minoti Hiremath, MBBS, PhD, Susan Yue, MD, Yan Sun, PhD, Willis Navarro, MD, Sarah Nikiforow, MD PhD

Blood (2019) 134 (Supplement_1): 4071.

https://doi.org/10.1182/blood-2019-124904

Published: 2019

Journal Articles

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

David A. Bond, MD, Vedat Yildiz, Lai Wei, PhD, Lapo Alinari, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Beth A. Christian, MD, Kristie A. Blum, MD, Kami J. Maddocks, MD

Blood (2019) 134 (Supplement_1): 4091.

https://doi.org/10.1182/blood-2019-130539

Published: 2019

Journal Articles

Pharmacological Inhibition of MAP2K7 Induces Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia

Taylor J Chen, BS, Ye Shen, PhD, Cory Seth Bridges, BS, Chun Shik Park, PhD, Jacob J. Junco, PhD, Karen R. Rabin, MD PhD, H. Daniel Lacorazza, PhD

Blood (2019) 134 (Supplement_1): 3889.

https://doi.org/10.1182/blood-2019-129127

Published: 2019

Journal Articles

Incidence of Invasive Fungal Infections in Acute Leukemia Patients Utilizing Micafungin Prophylaxis Compared to Second-Generation Azole Prophylaxis

Heather Morris, PharmD, BCPS, Meredith T. Moorman, PharmD, BCOP, CPP, Melissa C. Mackey, PharmD, BCPS, BCOP, Harry P. Erba, MD PhD, Thomas W. LeBlanc, MDMA,MHS, David A. Rizzieri, MD, Ian Barak, MS, Zhiguo Li, PhD, Tanya Zapolskaya, PharmD, BCPS, BCOP

Blood (2019) 134 (Supplement_1): 5105.

https://doi.org/10.1182/blood-2019-132197

Published: 2019

Journal Articles

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

David Hughes, PharmD, Frances Blevins, PA-C, Bhavesh Shah, RPh, Shayna Sarosiek, Adam Lerner, MD, John Mark Sloan, MD

Blood (2019) 134 (Supplement_1): 4912.

https://doi.org/10.1182/blood-2019-124740

Published: 2019

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

Multicenter Study of Ruxolitinibcombined DEP Regimen As a Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis

Jingshi Wang, Zhao Wang, MD PhD

Blood (2019) 134 (Supplement_1): 1042.

https://doi.org/10.1182/blood-2019-130980

Published: 2019

Journal Articles

Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura

Mouhamed Yazan Abou-Ismail, MD, Yasmin Arafah, MD, Pingfu Fu, PhD, Shufen Cao, Alvin H. Schmaier, MD, Lalitha V. Nayak, MD

Blood (2019) 134 (Supplement_1): 1084.

https://doi.org/10.1182/blood-2019-123537

Published: 2019

Journal Articles

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia

Lindsay Wilde, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD MS, Margaret Kasner, MDMSc

Blood (2019) 134 (Supplement_1): 2597.

https://doi.org/10.1182/blood-2019-131979

Published: 2019

Journal Articles

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Tim J Peterson, PharmD, Neha Korde, MD, Hani Hassoun, MD, Sham Mailankody, MBBS, Alexander M. Lesokhin, MD, Malin Hultcrantz, MD PhD, Urvi A Shah, MD, Eric L Smith, MD PhD, Sydney X Lu, MD PhD, Heather J Landau, MD, Gunjan L. Shah, MD, Michael Scordo, MD, Oscar B Lahoud, MD, Sergio A Giralt, MD, Ola Landgren, MD PhD

Blood (2019) 134 (Supplement_1): 5554.

https://doi.org/10.1182/blood-2019-124376

Published: 2019

NARROW

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Understanding How Fc-Modification Transforms a Pathogenic Heparin-Induced Thrombocytopenia (HIT)-like Monoclonal Antibody into a Novel Treatment for Sepsis

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Telomere Elongation and Clinical Improvement in Telomeropathy Patients: A Prospective Clinical Trial of Nandrolone in Telomeropathies

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

Pharmacological Inhibition of MAP2K7 Induces Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia

Incidence of Invasive Fungal Infections in Acute Leukemia Patients Utilizing Micafungin Prophylaxis Compared to Second-Generation Azole Prophylaxis

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

Infectious Complications Associated with CAR T-Cell Therapy

Multicenter Study of Ruxolitinibcombined DEP Regimen As a Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis

Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia

An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only